Surmodics | SRDX - Cash And Equivalent


Surmodics reported $36.11M in Cash and Equivalent for its fiscal quarter ending in September of 2024.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
Align Technology USD 1B 103.43M Sep/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Baxter International USD 1.73B 40M Sep/2025
Boston Scientific USD 1.28B 741M Sep/2025
EDAP TMS EUR 29.84M 4.35M Dec/2024
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Haemonetics USD 363.37M 66.94M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Merit Medical Systems USD 392.46M 50.64M Sep/2025
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Option Care Health USD 309.82M 111M Sep/2025
Stryker USD 4.01B 755M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Trinity Biotech USD 1.34M 3.83M Sep/2025